Quick Answer
Nuvation Bio Inc. reported Cash and Equivalents of $164.09 million for fiscal year 2025.
Nuvation Bio Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $164.09M | +359.3% |
| 2024 | $35.72M | -16.2% |
| 2023 | $42.65M | -57.8% |
| 2022 | $101.10M | -23.7% |
| 2021 | $132.42M | +345.0% |
| 2020 | $29.75M | — |
| 2020 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $98.90M | +229.3% | -60.1% |
| June 30, 2025 | $247.97M | +623.3% | +416.9% |
| March 31, 2025 | $47.98M | +39.0% | +34.3% |
| December 31, 2024 | $35.72M | -16.2% | +18.9% |
| September 30, 2024 | $30.04M | +23.1% | -12.4% |
| June 30, 2024 | $34.28M | -31.5% | -0.7% |
| March 31, 2024 | $34.51M | +14.8% | -19.1% |
| December 31, 2023 | $42.65M | -57.8% | +74.8% |
- Nuvation Bio Inc. showed an increase of +359.3% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Nuvation Bio Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: